{"id":"gp2013-a-proposed-biosimilar-rituximab","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion reactions"},{"rate":"15-25","effect":"Infections"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Anemia"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a biosimilar of rituximab, GP2013 targets the CD20 antigen expressed on the surface of B lymphocytes. Upon binding, it triggers B cell destruction through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby reducing pathogenic B cell populations in autoimmune and hematologic conditions.","oneSentence":"GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:13.063Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"},{"name":"Granulomatosis with polyangiitis"},{"name":"Microscopic polyangiitis"}]},"trialDetails":[{"nctId":"NCT02514772","phase":"PHASE3","title":"GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®","status":"COMPLETED","sponsor":"Sandoz","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":107}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP2013 - A Proposed biosimilar rituximab","genericName":"GP2013 - A Proposed biosimilar rituximab","companyName":"Sandoz","companyId":"sandoz","modality":"Biologic","firstApprovalDate":"","aiSummary":"GP2013 is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduction of autoimmune activity. Used for Rheumatoid arthritis, Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}